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Abstract Evaluation of prognostic factors in lymph node
negative (LNneg) invasive lobular cancers (ILCs). Pro-
spective analysis of proliferation and other prognosticators
in 121 LNneg ILCs (119 months median follow-up, range
19–181), without adjuvant chemotherapy. ILC subtype was
assessed in accordance with WHO-2003 criteria. Immu-
nohistochemical E-cadherin and estrogen receptor were
used. With a median follow up time of 83 months (range
19–181), 30 of the 121 (25%) ILC patients developed
distant metastases and 27 (22%) died. None of the cases
classified as solid/pleomorphic lobular were E-cadherin or
estrogen receptor positive, contrasting the other ILCs. The
solid/alveolar ILCs (n = 17) had a worse survival (50%)
than the other ILCs (n = 104; 83%, P \ 0.0001). Mitotic
activity index (MAI) (but not nuclear grade or tubule
formation) was prognostic with a threshold 0–5 versus [5
(=MAI-5) (contrasting MAI \ 10 vs. C10 in breast cancers
in general; 85 and 54% survival, P \ 0.0001). In multi-
variate analysis only subtype and MAI but none of the
other characteristics had independent prognostic value.
Histologic subtype and MAI have independent prognostic
value in node negative invasive lobular cancers.
Keywords Lobular invasive breast cancer  Prognosis 
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Introduction
Invasive lobular cancers (ILCs) form about 10% of all
primary breast carcinomas, and the incidence may be
increasing [1]. It is generally believed that ILC is a dif-
ferent entity from invasive ductal carcinoma (IDC) as the
response to pre-operative chemotherapy in ILCs may be
worse, with a greater need for rescue mastectomy. This
lesser response in ILC than in IDC is correlated to their
immunohistochemical profile [2]. It is thus important that
the biological prognostic characteristics of ILCs should be
studied further in order to make the fine-tuning of treatment
possible [3].
A classical study [4] analyzed the factors which are
prognostic in ILC. In addition to the disease stage at pre-
sentation, the other major significant factor in predicting
survival was histological subtype. A recent very large study
compared 4,140 ILC and 45,169 (not otherwise specified)
IDC patients [5] and found that despite the fact that the
biological phenotype of ILC seemed quite favorable, the
clinical outcome of those patients was not better than that
of patients with IDC. The authors concluded that different
management decisions should be based on individual
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patient and tumor biologic characteristics, than lobular
histology.
Immunohistochemical analysis of E-cadherin has led to
the identification of new variants of lobular carcinoma
associated with a more aggressive clinical behavior [6].
Proliferation variables such as tritiated thymidine labeling
index and mitotic activity index (MAI) are strong prog-
nostic factors in invasive breast cancer [7]. The MAI is also
prognostic in small tumors of \1 cm, and grades 1 ? 2
tumors between 1 and 3 cm diameter, which are not usually
treated with adjuvant chemotherapy [8]. It was found that
the histologic grade (in which the MAI plays an important
role) is prognostic in ILC, but the different constituents of
grade (MAI, tubule formation, nuclear atypia) were not
analyzed separately [8]. Proliferation is usually low in
ILCs, though in rare cases mitoses can be frequent. As it is
uncertain what the prognostic value of this phenomenon is
in ILCs, we have prospectively studied these interesting
occurrences in comparison with other characteristics in the
large multicenter material of the MMMCP study [7],
involving 2,274 invasive breast cancers.
Patients and methods
Patients
Details of the prospective multicenter MMMCP study have
been described elsewhere [7]. The study has been approved
by the Regional Ethics Committee of the VU Medical
center and collaborating hospitals. All consecutive primary
invasive breast cancer patients diagnosed in the collabo-
rating hospitals were enrolled, and the follow-up was
updated annually. The guidelines for reporting tumor
marker studies [9] were followed. Out of 3,479 MMMCP
patients registered, 138 were not invasive; 10 had sarco-
mas; 32 had metastases at the time of diagnosis; 235 were
not operable or the operation was not curative from the
onset; 242 had previous or concurrent malignancies (other
than basal cell carcinoma or cervical carcinoma in
situ = CIS); 42 were double sided, and 460 were lost to
follow-up. This left 2,274 patients with invasive cancers
for further study. In 92 patients including 4 invasive lobular
cancers, no axillary lymph node dissection was done for
various reasons (old age n = 46, already distant metastases
at the time of operation n = 6, patient refused axillary
dissection n = 6, cancer diameter [ 5 cm n = 5, thoracic
wall invasion n = 7, poor clinical non-breast cancer-rela-
ted conditions n = 12, reason unknown n = 10). All
remaining 2,182 patients were treated with modified radical
mastectomy (MRM, n = 1,141) or breast-conserving
therapy (BCT, n = 1,041), always with adequate axillary
lymph node dissection (median 11 lymph nodes detected in
the axillary lymph node dissection specimens). Figure 1
illustrates which patients from the prospective multicenter
MMMCP study were used in the current study on lymph
node negative lobular invasive breast cancer. Loco-regio-
nal radiotherapy was given in cases that underwent breast-
conserving therapy or had medially localized tumors. None
of the patients received any form of adjuvant chemo or
hormonal therapy.
Pathology
Post-surgical size of the tumor (pT) was measured in the
fresh specimens; the tumors were cut into slices of 0.5 cm,
fixed in buffered 4% formaldehyde, and embedded in
paraffin. Paraffin sections of 4mm thickness were cut and
stained with hematoxylin and eosin. Histologic grade and
type were assessed in many participating centers and
independently reviewed by three of us (JB, PD and E.G)
with considerable experience in breast pathology. Invasive
lobular cancers were defined using the World Health
Organization (WHO) criteria [1] as cancers composed of
non-cohesive cells individually dispersed or arranged in
single-file linear pattern (often referred to as ‘Indian fil-
ing’), often associated with lobular carcinoma in situ
= LCIS, frequently with a diffuse growth pattern or cell
infiltrate, and usually with a concentric ‘‘targetoid’’ pattern
around normal ducts. Grade was assessed, again according
to the WHO criteria using MAI 0–5 = 1, 6–10 = 2 and
[10 as 3, nuclear atypia as mild = 1, moderate = 2 and
marked = 3, and tubule formation as much ([75%) = 1,
minimal (\10%) = 3 and intermediate (10–75%) = 2. At
careful review of type 1,812 cancers were ductal; 113
ductal combined with other types (but non-lobular); 201
lobular invasive; 23 tubular; 22 colloid; 11 medullary, and
2 were papillary (total = 2,184). As the non-lobular non-
ductal cancers were relatively rare and also had a much
better prognosis than the ILCs and IDCs, they were not
further considered in the present study.
Of the 201 lobular invasive cancers, 121 were LNneg,
and sub-typed independently by two of us (E.G, JB). LCIS
was characterized by extended lobules with a solid typical
cell pattern without lumina, consisting of cells with
remarkably round and regular nuclei with regular spacing,
often with somewhat more cytoplasm than in ductal can-
cers and frequently containing cytoplasmic vacuoles. The
pleomorphic and solid variants may cause differential
diagnostic problems with classical (‘‘Indian filing’’) ILC on
one hand (for the pleomorphic ILCs) and ductal grade 3
cancers (for the solid ones) on the other. To avoid this,
using WHO 2004 criteria we defined ILCs as pleomorphic
if they had clearly large and round rather than molded
small nuclei located in Indian files of one, or at maximum,
focally two cells thickness. To avoid a false inclusion of
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ductal grade 3 cancers, the following characteristics of
LCIS or Indian filing with targetoid growth pattern should
be present to classify a cancer as an ILC, solid subtype.
Presence of extensive necrosis occurred in one solid cancer
which is unusual in solid ILCs, and therefore this case was
excluded as well, also due to the E-cadherin staining result.
In all cases classified as pleomorphic or solid, E-cadherin
staining was done using normal glands in the same sections
as internal controls. The non-lobular ductal combinations
were regarded as ductal, but the ductulo-lobular cancers
were regarded as a lobular subtype variant; they had the
same survival as the ductal and the non-solid-non-pleo-
morphic lobular subtype cancers. The resection margins in
the biopsies were evaluated as free or not free of tumor.
Estrogen receptor value (ER) was assessed in reference
laboratories by charcoal technique (cut off 10 fmol/mg
protein). For the ER negative cases, immunohistochemical
analysis was done.
Immunohistochemistry
E-Cadherin was done as described in all solid and pleo-
morphic cases to exclude E-Cadherin positive grade 3
ductal cancers. Antigen retrieval and antibody dilution
were optimized prior to the study onset. To ensure uniform
handling of samples, all sections were processed simulta-
neously. Paraffin sections adjacent to the H&E sections
used for assessment of MAI and histology were dried
overnight at 37C followed by 1 h at 60C. Sections were
deparaffinized in xylene and rehydrated by decreasing the
concentration of alcohol. Antigen was retrieved from a
highly stabilized retrieval system (ImmunoPrep, Instrumec,
Oslo, Norway) using 10 mM Tris/1 mM EDTA (pH 9.0) as
the retrieval buffer. Sections were heated for 3 min at
110C followed by 10 min at 95C and cooled to 20C.
Rabbit monoclonal ER (clone SP1 Thermo Scientific,
Fremont, USA) was used at a dilution of 1/400 and
E-Cadherin (Clone 36B5, Novocastra Laboratories ltd,
Newcastle upon Tyne, UK) was used at a dilution of 1/50.
The sections were incubated for 45 min at 22C. Dako
antibody diluent (S0809) was used. Endogenous peroxidase
activity was blocked with a peroxidase-blocking reagent
(S2001; Dako) for 10 min. The immune complex was
visualized by the Dako REAL EnVision Detection System,
Peroxidase/DAB, Rabbit/Mouse (K5007; Dako). Sections
were incubated with EnVision/HRP, Rabbit/Mouse for
30 min, and diaminobenzidine (DAB?) chromogen for
10 min. The sections were counterstained with hematoxy-
lin, dehydrated, and mounted. All steps were performed
using Dako Autostainer and TBS (S1968; Dako) with
0.05% Tween 20 as wash buffer.
Mitosis counts and nuclear morphometry
Following the MMMCP protocol, the total number of well-
defined mitotic figures was counted at the time of diagnosis
at 4009 magnification (objective 40, field diameter
450 lm at specimen level) in 10 consecutive neighboring
fields of vision in the most poorly differentiated peripheral
area of the tumor (=measurement area, representing a total
area of 1.59 mm2). Fields with necrosis or inflammation
were avoided, and doubtful structures were ignored. The
resulting total number of mitosis in the ten fields of vision
is the MAI. An accurate MAI assessment takes 3–5 min.
Correction of MAI for the percentage of tissue occupied by
stroma or the number of tumor cells was not applied since
it was previously shown that this does not substantially
improve the prognostic value of the MAI and ismore time
consuming. The MAI is a continuous variable, and
according to many previous studies, the most important
3479 patients initially  registered
in the MMMCP study
2274 patient left for further study
1205 patients excluded based on clinical
92 patients without axillary lymph-node dissection
2182 patients with invasive cancer
1981 patients independently reviewed as non-ILC
201 patients with ILC
80 patients with lymph node metastases
121 lymph-node negative patients 
included in study
-
Fig. 1 Flow-sheet diagram
depicting which patients from
the prospective multicenter
MMMCP study were used for
the current study on lymph node
negative lobular invasive breast
cancer
Breast Cancer Res Treat (2010) 121:35–40 37
123
prognostic threshold for the whole group is MAI \ 3
(excellent prognosis), 3–10 (favorable prognosis) versus
C10 (poor prognosis). We also analyzed the classical
Nottingham thresholds (0–5, 6–10 and [10).
Nuclear morphometric analysis of the representative
H&E sections used for revision grading was performed
with an image analysis system (Leica, Cambridge, UK) at
1,8009 screen magnification, using rigid point-weighted
systematic random sampling [10]. This guarantees unbi-
ased high reproducibility and stronger prognostic value
[11]. At least 50 and a maximum of 225 (median: 79)
nuclei were measured per case (one nucleus per field of
vision) and the mean nuclear area was calculated. The total
number of nuclei per case was determined by the coeffi-
cient of error (CE) of the ongoing measurements per case.
The CE was continuously calculated and if it fell under 5%,
the measurement was terminated but only if a minimum of
50 nuclei was measured. Intra- and inter-observer repro-
ducibility of this method has previously proven to be very
high [12].
Statistical analysis
Main endpoints were distant recurrence (Metastases-Free
Survival = MFS) and mortality due to distant metastases
(Overall Survival = OS). In analyzing the probability that
patients would remain free of distant metastases, we defined
recurrence as any first recurrence at distant sites. All other
patients were censored on the date of the last follow-up visit
and included deaths from causes other than breast cancer,
local, or regional recurrences or the development of a sec-
ondary primary cancer (including contra-lateral breast
cancer). Mortality was defined as any death due to distant
metastases (as evident from clinical, radiologic, histologic,
or autopsy data) (no patients died from loco-regional dis-
ease). If the cause of death was unknown, but a metastasis
was previously detected, then death was considered as
breast cancer related unless explicitly stated otherwise (in
line with other studies) [1]. If the status during follow-up
indicated a confirmed metastasis without a date of recur-
rence, the date of that follow-up visit was used. SPSS
version 13 (SPSS, Chicago, USA) was used for the analyses.
Age, time to first recurrence, and survival time were cal-
culated relative to the date of primary diagnosis. Continu-
ous variables were discretized according to previously
described thresholds, or dividing the whole group into
subgroups according to the medians, tertiles, or quartiles.
Moreover, Receiver Operator Curves were used for
assessing the optimal threshold. Survival curves were con-
structed using Kaplan-Meier techniques. Differences
between groups were tested by log-rank tests or tests for
trend. The relative importance of potential prognostic
variables was tested using Cox-proportional hazard analysis
and expressed in Hazards Ratio (HR) with 95% confidence
intervals.
Results
None of the invasive lobular cancers classified as solid/
pleomorphic lobular were E-Cadherin or estrogen receptor
positive, contrasting the other ILCs. With a median follow-
up time of 83 months (range: 19–181), thirty of the 121
(25%) ILC patients developed distant metastases and of
these 27 (22%) died. The histological ILC subtype was a
strong prognosticator, but only the survival difference
between the Solid and Alveolar (=SA) ILC subtypes
together (n = 17) versus all other subtypes was significant.
Therefore, SA-ILCs had a much worse prognosis than the
other ILCs (41 versus 84% survival, P \ 0.0001, Hazard
Ratio = 6.0, 95% Confidence Interval = 95% CI = 2.8–
13.0; Fig. 2). The MAI (but not nuclear grade, nor tubular
formation or histologic grade) was prognostic but the
strongest threshold was 0–5 (n = 93) versus [5 [n = 28;
MAI-5; contrasting the previously described threshold of
0–9 vs. C10 in general (mostly ductal) cancers]; the sur-
vival rates of 10 years were 85 and 54%, P \ 0.0001,
HR = 3.9, 95% CI = 1.8–8.4 (Fig. 3). The other features
were (less) significant (0.05 \ P \ 0.01) with univariate
survival analysis.
With multivariate analysis, histologic subtype (as SA-
ILCs versus all other subtypes) and MAI had independent
statistical and clinically relevant value (in sequence of
decreasing significance; P \ 0.0001). This combination
overshadowed all other univariately significant features.
MAI-5 added to the histologic subtype but this was sig-
nificant only in the non-SA ILCs (MAI 0–5 and[5: 87 and
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Fig. 2 Survival curves of the lobular invasive cancers stratified over
histologic subtype
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67% overall survival respectively, P = 0.04, HR = 2.8,
95% CI = 1.1–7.6) and not in the SAs-ILC (57 and 30%
overall survival, P = 0.42).
Discussion
The current large prospective multicenter material on
lymph node negative invasive lobular cancers without
systemic adjuvant treatment showed that the characteristics
in the present study are comparable to other previous
studies, making the results representative for LNneg lob-
ular invasive cancer in general. ILC-subtype and MAI are
prognostically the most important. The fact that MAI was
prognostic, rather than tubule formation, nuclear atypia and
grade is in agreement with a previous study on breast
cancer in general [13]. What is new is the fact that MAI
with a threshold of five and not ten is one of the three most
important prognosticators in the lobular invasive cancers,
which explains why the prognostic value of the MAI in
breast cancer varies in different studies. Using the classical
prognostic threshold of ten works well for the ductal but
not for the ILC subtype cancers, whereas in the ILC can-
cers, MAI-5 will prognosticate best. Consequently,
depending on the mix of ductal and lobular cancers, the
prognostic thresholds of the MAI will vary. The prognostic
value of the MAI is therefore distorted when histologically
different groups are mixed (i.e., ductal and lobular cancers)
with prognostically different MAI thresholds.
The fact that histologic subtype appeared to be a
strongly significant prognosticator is in agreement with a
previous classical study using both lymph node negative
and positive ILCs [14] (we studied lymph node negative
ILCs only). The reproducibility of the solid and alveolar
ILCs on the one hand and grade 3 ductal cancers on the
other therefore becomes important. Alveolar cancers are
easy to recognize and should not offer a serious problem if
the pathologist is well trained. We have used strict, widely
available and applicable WHO 2003 criteria to guarantee
correct classification which, in our hands as experts in
breast pathology was well reproducible, though in a routine
practice of general surgical pathologists, reproducibility
may sometimes be less good. This can be regarded as a
drawback to give histologic subtype in ILCs such a
prominent prognostic role. However, this objection is much
less important than it seems as immunohistochemistry
(E-Cadherin, oestrogen receptor) is of great help. Even if
pathologists erroneously classify a lobular cancer as ductal,
then MAI can still predict prognosis correctly if MAI is
C10. Only in the relatively few cases with MAI 6–10
(which occurs in only 10% of all ILCs), one would get a
too favorable prognostic impression if the cancer with a
MAI between 5 and 10 is erroneously classified as a ductal
grade 3, instead of a solid ILC. Strict use of the classifi-
cation criteria, and additional immunohistochemical
E-cadherin, and ER analysis is therefore of importance and
enhances the significance of an accurate pathologic diag-
nosis in determining the true outcome of the patient.
We conclude that in node negative lobular invasive
cancers, histologic subtype and MAI with a threshold of
five (rather than MAI with a threshold of ten, tubular for-
mation, nuclear atypia and grade) have independent and
prognostic value.
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